BioLife Solutions (NASDAQ:BLFS) Rating Lowered to Sell at BidaskClub
BLFS has been the subject of several other reports. Zacks Investment Research downgraded ExlService from a “hold” rating to a “sell” rating in a research report on Wednesday, July 10th. Maxim Group set a $24.00 target price on BioLife Solutions and gave the stock a “buy” rating in a research report on Wednesday, May 22nd. Northland Securities lifted their target price on Paycom Software from $215.00 to $275.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 9th. Finally, ValuEngine upgraded XCel Brands from a “sell” rating to a “hold” rating in a report on Tuesday, July 9th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. BioLife Solutions currently has a consensus rating of “Buy” and a consensus price target of $17.80.
NASDAQ:BLFS opened at $16.93 on Friday. BioLife Solutions has a twelve month low of $9.15 and a twelve month high of $26.35. The company has a market capitalization of $318.27 million, a P/E ratio of 120.93 and a beta of 1.31. The stock’s fifty day simple moving average is $17.22. The company has a debt-to-equity ratio of 0.02, a quick ratio of 12.99 and a current ratio of 14.50.
In related news, major shareholder Walter Villiger sold 39,883 shares of BioLife Solutions stock in a transaction dated Tuesday, May 21st. The stock was sold at an average price of $19.18, for a total value of $764,955.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP James Mathers sold 2,500 shares of BioLife Solutions stock in a transaction dated Tuesday, July 9th. The shares were sold at an average price of $17.94, for a total value of $44,850.00. Following the completion of the sale, the vice president now owns 19,884 shares of the company’s stock, valued at $356,718.96. The disclosure for this sale can be found here. Insiders sold 213,871 shares of company stock valued at $3,773,339 over the last 90 days. 27.00% of the stock is currently owned by corporate insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Cadence Capital Management LLC grew its stake in BioLife Solutions by 1.8% in the first quarter. Cadence Capital Management LLC now owns 195,269 shares of the medical equipment provider’s stock valued at $3,493,000 after purchasing an additional 3,439 shares during the last quarter. FMR LLC purchased a new position in BioLife Solutions in the first quarter valued at about $2,684,000. Granite Investment Partners LLC grew its stake in BioLife Solutions by 25.5% in the first quarter. Granite Investment Partners LLC now owns 103,109 shares of the medical equipment provider’s stock valued at $1,845,000 after purchasing an additional 20,947 shares during the last quarter. Ranger Investment Management L.P. purchased a new position in BioLife Solutions in the fourth quarter valued at about $1,108,000. Finally, Laurion Capital Management LP grew its stake in BioLife Solutions by 74.0% in the first quarter. Laurion Capital Management LP now owns 84,944 shares of the medical equipment provider’s stock valued at $1,520,000 after purchasing an additional 36,136 shares during the last quarter. Institutional investors own 45.76% of the company’s stock.
About BioLife Solutions
BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.
Read More: What is a CD ladder?
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.